Audi Francesca Setiadi

Dr. Audi Francesca Setiadi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in The Lancet Haematology
Verified
Journal Article
Closed access
ASAudi Francesca Setiadi
Audi Francesca Setiadi
AZAdi Zoref-Lorenz
Adi Zoref-Lorenz
CLChristina Y Lee
Christina Y Lee
MJMichael B Jordan
Michael B Jordan
LCLuke Y C Chen
Luke Y C Chen

27 October 2022 in Blood
Verified
Journal Article
Closed access
PDF file
MSMehul Sharma
Mehul Sharma
MFMaggie P. Fu
Maggie P. Fu
HLHenry Y. Lu
Henry Y. Lu
ASAshish Sharma
Ashish Sharma
BMBhavi P. Modi
Bhavi P. Modi
STStuart E. Turvey
Stuart E. Turvey
The discovery of humans with monogenic disorders has a rich history of generating new insights into biology. Here we report the first human identified with complete deficiency of nuclear factor of activated T cells 1 (NFAT1). NFAT1, encoded by NFATC2, mediates calcium-calcineurin signals that drive cell activation, proliferation, and survival. The patient is homozygous for a damaging germline NFATC2 variant (c.2023_2026delTACC; p.Tyr675Thrfs∗18) and presented with joint contractures, osteochondromas, and recurrent B-cell lymphoma. Absence of NFAT1 protein in chondrocytes caused enrichment in prosurvival and inflammatory genes. Systematic single-cell–omic analyses in PBMCs revealed an environment that promotes lymphomagenesis with accumulation of naïve B cells (enriched for oncogenic signatures MYC and JAK1), exhausted CD4+ T cells, impaired T follicular helper cells, and aberrant CD8+ T cells. This work highlights the pleiotropic role of human NFAT1, will empower the diagnosis of additional patients with NFAT1 deficiency, and further defines the detrimental effects associated with long-term use of calcineurin inhibitors.

28 December 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MGMariam Goubran
Mariam Goubran
CSCaroline Spaner
Caroline Spaner
SSSophie Stukas
Sophie Stukas
AZAdi Zoref-Lorenz
Adi Zoref-Lorenz
KSKamran Shojania
Kamran Shojania
ASAudi Francesca Setiadi
Audi Francesca Setiadi
Cytokine storm syndromes such as hemophagocytic lymphohistiocytosis (HLH), Adult-onset Still’s disease (AOSD), and COVID-19 cytokine storm (CCS) are characterized by markedly elevated inflammatory cytokines. However clinical measurement of serum cytokines is not widely available. This study examined the clinical utility of C-reactive protein (CRP) and ferritin, two inexpensive and widely available inflammatory markers, for distinguishing HLH from AOSD and CCS. This single centre retrospective study included 44 secondary HLH patients, 14 AOSD patients, and 13 CCS patients. Baseline CRP and ferritin measured within 72 h of diagnosis and before administration of corticosteroids or other anti-inflammatory therapies were analyzed. The median CRP in HLH patients was lower than AOSD (71 mg/L vs. 172 mg/L, p < 0.001) and CCS (71 mg/L vs. 121 mg/L, p = 0.0095) patients. Serum ferritin levels were lower in CCS compared to HLH (1,386 µg/L vs. 29,019 µg/L, p < 0.001) and AOSD (11,359 µg/L vs. 29,019 µg/L, p = 0.035). A CRP < 130 mg/L when combined with an HScore > 136 improves the specificity of HScore alone for HLH from 85.2 to 96.3%. Adding CRP < 130 mg/L to ferritin > 15,254 µg/L increases specificity for HLH from 88.9 to 100%. This study demonstrates that median CRP is lower in HLH than in AOSD and CCS, and median ferritin is lower in CCS than in HLH or AOSD. This study demonstrates the clinical utility of these widely available inflammatory markers for distinguishing between different cytokine storm syndromes.

10 July 2024 in European Journal of Haematology
Verified
Journal Article
Open access
MBMadelaine Beckett
Madelaine Beckett
CSCaroline Spaner
Caroline Spaner
MGMariam Goubran
Mariam Goubran
JWJohn Wade
John Wade
JAJuan Antonio Avina‐Zubieta
Juan Antonio Avina‐Zubieta
LCLuke Y. C. Chen
Luke Y. C. Chen
Objective: Adult‐onset Still's disease (AOSD) and secondary hemophagocytic lymphohistiocytosis (sHLH) are both hyperferritinemic cytokine storm syndromes that can be difficult to distinguish from each other in hospitalized patients. The objective of this study was to compare the inflammatory markers ferritin, D‐dimer, C‐reactive protein (CRP), and soluble CD25 (sCD25) in patients with AOSD and sHLH. These four markers were chosen as they are widely available and represent different aspects of inflammatory diseases: macrophage activation (ferritin); endothelialopathy (D‐dimer); interleukin‐1/interleukin‐6/tumour necrosis factor elevation (CRP) and T cell activation (sCD25).Methods: This was a single‐center retrospective study. Patients diagnosed by the Hematology service at Vancouver General Hospital for AOSD or sHLH from 2009 to 2023 were included.Results: There were 16 AOSD and 44 sHLH patients identified. Ferritin was lower in AOSD than HLH (median 11 360 μg/L vs. 29 020 μg/L, p = .01) while D‐dimer was not significantly different (median 5310 mg/L FEU vs. 7000 mg/L FEU, p = .3). CRP was higher (median 168 mg/L vs. 71 mg/L, p <.01) and sCD25 was lower (median 2220 vs. 7280 U/mL, p = .004) in AOSD compared to HLH. The combined ROC curve using CRP >130 mg/L and sCD25< 3900 U/mL to distinguish AOSD from HLH had an area under the curve (AUC) of 0.94 (95% confidence interval 0.93–0.97) with sensitivity 91% and specificity 93%.Conclusions: These findings suggest that simple, widely available laboratory tests such as CRP and sCD25 can help clinicians distinguish AOSD from HLH in acutely ill adults with extreme hyperferritinemia. Larger studies examining a wider range of clinically available inflammatory biomarkers in a more diverse set of cytokine storm syndromes are warranted.

13 June 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
MAMaryam Al‐Bakri
Maryam Al‐Bakri
JTJefferson Terry
Jefferson Terry
KCKate Chipperfield
Kate Chipperfield
DMDouglas Morrison
Douglas Morrison
ASAudi Francesca Setiadi
Audi Francesca Setiadi

3 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MSMehul Sharma
Mehul Sharma
MFMaggie P. Fu
Maggie P. Fu
HLHenry Y. Lu
Henry Y. Lu
ASAshish A. Sharma
Ashish A. Sharma
BMBhavi P. Modi
Bhavi P. Modi
STStuart E. Turvey
Stuart E. Turvey
Discovery of humans with monogenic disorders has a rich history of generating new insights into biology. Here we report the first human identified with complete deficiency of nuclear factor of activated T cells 1 (NFAT1). NFAT1, encoded by NFATC2 , mediates calcium-calcineurin signals that drive cell activation, proliferation, and survival. The patient is homozygous for a damaging germline NFATC2 variant (c.2023_2026delTACC; p.Tyr675Thrfs*18) and presented with joint contractures, osteochondromas, and B cell lymphoma. Absence of NFAT1 protein in chondrocytes caused enrichment in pro-survival and inflammatory genes. Systematic single-cell-omic analyses revealed an environment that promotes lymphomagenesis with accumulation of naïve B cells (with oncogenic signatures - MYC , JAK1 ), exhausted CD4 + T cells, impaired T follicular helper cells, and aberrant CD8 + T cells. This work highlights the pleiotropic role of human NFAT1, will empower the diagnosis of additional patients with NFAT1 deficiency, and further define detrimental effects a long-term use of calcineurin inhibitors.